Related Experiment Video
Updated: Jun 16, 2026
07:15
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Genetic testing in cardiovascular diseases
Nynke Hofman1, Irene van Langen, Arthur A M Wilde
1Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands.
Current Opinion in Cardiology
|February 19, 2010
Summary
Genetic counseling and testing for inherited heart disease are expanding, with growing diagnostic yields from new genetic discoveries. Further research is needed to understand mutation relevance and optimize cascade screening for timely patient treatment.
Area of Science:
- Cardiovascular Genetics
- Medical Genetics
- Genomic Medicine
Background:
- Inherited heart diseases (IHDs) represent a significant clinical challenge.
- Genetic counseling and testing are crucial for diagnosing and managing IHDs.
- Advances in molecular diagnostics are rapidly evolving.
Purpose of the Study:
- To review the current landscape of genetic counseling and testing for IHDs.
- To assess the diagnostic yield and patient perspectives.
- To discuss future directions and optimization strategies.
Main Methods:
- Literature review of recent studies on genetic counseling and testing in IHDs.
- Analysis of gene-specific studies, such as for long QT syndrome.
- Examination of patient follow-up and perspective research.
Main Results:
- A rapid increase in the number of individuals undergoing genetic counseling globally.
- Emerging research on patient perspectives and long-term follow-up.
- Progress in gene-specific studies to evaluate the clinical significance of identified mutations.
Conclusions:
- The diagnostic yield of genetic testing for IHDs is rapidly increasing due to new gene discoveries and improved techniques.
- Ongoing research is essential to determine the clinical relevance of identified genetic variants.
- Optimizing genetic counseling through cascade screening can identify at-risk individuals for timely intervention.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...